Xeris officer sells 45K shares in pre-set plan

Xeris Biopharma Holdings insider Steven Pieper reported open-market sales of 45,000 shares of common stock over two days.

Rhea-AI Filing Summary

Xeris Biopharma Holdings insider Steven Pieper reported open-market sales of 45,000 shares of common stock over two days. He sold 27,600 shares on July 7, 2026 at a weighted average price of $8.5245 per share and 17,400 shares on July 6, 2026 at $8.50 per share.

After these transactions, Pieper directly holds 1,366,053 Xeris Biopharma shares. The filing notes the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, and that his holdings include 2,113 shares acquired on June 30, 2026 through the company’s Employee Stock Purchase Plan.

Insider Trade Summary 10b5-1

Net Seller: 45,000 shares

Net Sell 2 txns

Insider Pieper Steven

Role See Remarks

Sold 45,000 shs ($383K)

Type	Security	Shares	Price	Value
Sale	Common Stock	27,600	$8.5245	$235K
Sale	Common Stock	17,400	$8.50	$148K

Holdings After Transaction: Common Stock — 1,366,053 shares (Direct)

Footnotes (3)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.
2. F2. Includes 2,113 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.
3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Total shares sold: 45,000 shares Shares sold on July 7, 2026: 27,600 shares Shares sold on July 6, 2026: 17,400 shares +3 more

6 metrics

Total shares sold 45,000 shares Open-market sales on July 6–7, 2026

Shares sold on July 7, 2026 27,600 shares Common stock at $8.5245 weighted average

Shares sold on July 6, 2026 17,400 shares Common stock at $8.50 per share

Shares held after transactions 1,366,053 shares Direct ownership after July 7, 2026 sale

ESPP shares included 2,113 shares Acquired June 30, 2026 under 2018 Employee Stock Purchase Plan

Sale price range $8.50–$8.60 per share Multiple trades making up weighted average price

Key Terms

Rule 10b5-1 trading plan, Employee Stock Purchase Plan, weighted average price, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Purchase Plan financial

"Includes 2,113 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

How many XERS shares did Steven Pieper sell in this Form 4?

Steven Pieper sold a total of 45,000 shares of Xeris Biopharma common stock. The sales occurred in two transactions on July 6 and July 7, 2026, as disclosed in the Form 4 filing.

At what prices did Steven Pieper sell Xeris Biopharma (XERS) shares?

Pieper sold Xeris Biopharma shares at $8.50 and a weighted average of $8.5245 per share. The filing notes multiple trades between $8.50 and $8.60, resulting in the reported average sale price.

How many Xeris Biopharma (XERS) shares does Steven Pieper hold after these sales?

After the reported sales, Steven Pieper directly holds 1,366,053 shares of Xeris Biopharma common stock. This post-transaction ownership figure is disclosed in the Form 4 for the July 7, 2026 transaction.

Were Steven Pieper’s XERS stock sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 trading plan. This plan was adopted by Steven Pieper on August 18, 2025, indicating the sales were pre-arranged rather than newly decided.

Did Steven Pieper acquire any XERS shares through an employee plan before these sales?

Yes. The filing notes that his holdings include 2,113 shares acquired on June 30, 2026. These shares were obtained under Xeris Biopharma’s 2018 Employee Stock Purchase Plan, as amended.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/07/2026 - 05:11 PM Accepted by SEC EDGAR 07/07/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pieper Steven

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/06/2026		S(1)		17,400	D	$8.5	1,393,653(2)	D
Common Stock	07/07/2026		S(1)		27,600	D	$8.5245(3)	1,366,053	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

2. Includes 2,113 shares acquired on June 30, 2026 under the issuer's 2018 Employee Stock Purchase Plan, as amended.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

Chief Financial Officer

	/s/ Beth Hecht, Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)